Tuesday, February 17, 2026 2/17/2026

Translational Metabolomics in Critical Care

Award Number: R35GM136312
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2020
PERIOD OF PERFORMANCE END DATE: 01/31/2030

Group Awards By:

View Award Description

Translational Metabolomics in Critical Care - Sepsis and other critical illnesses remain significant hazards to human health. Sepsis and the Acute Respiratory Distress Syndrome (ARDS) are particularly challenging because they are associated with great heterogeneity that has kept the identification of diagnostic and predictive biomarkers and effective pharmacotherapy elusive. To tackle the problem of critical illness heterogeneity, my research program employs Translational Metabolomics which bridges the translational gap between analytical and experimental techniques and the clinical application of the science of metabolomics. To achieve my goals, I have innovative swine models of sepsis and ARDS that faithfully recapitulate the human situations, ready access to human sepsis cohorts for clinical validation, novel point-of-care (POC) technology and can assay clinical and experimental biospecimens using a range of analyt- ical platforms including liquid chromatography (LC)-mass spectroscopy (MS) and quantitative nuclear magnetic resonance (NMR). Over the last four years of MIRA funding, I have advanced understanding about the meta- bolic mechanisms that underlie sepsis morbidity and mortality, identified a metabolic signature that is predictive of these outcomes, and uncovered a relationship between angiopoietin (ANG) 2 blood levels and phenotypes of sepsis and ARDS. Under this MIRA renewal application, I will advance these initiatives to achieve the over- arching and long-term goal of my program which is to move metabolomics from knowledge discovery to imple- mentation that will transform the care of patients with critical illnesses. To achieve this, I will address four key questions: 1) How do gut pH and gut microbial metabolites contribute to the heterogeneity of sepsis? 2) Does inhibition of ANG 2 intensify sepsis-induced disruption in energy homeostasis or improve end-organ function? 3) What is the predictive value of blood acetylcarnitine concentration for sepsis induced organ dysfunction, per- sistent critical illness, and mortality? and 4) Does supplemental L-carnitine remedy the loss of cardiac meta- bolic homeostasis during sepsis? By addressing these critical questions, we will gain novel insights into the role of gut pH in sepsis heterogeneity, learn about the metabolic contribution of ANG 2 in ARDS, further cre- dential acetylcarnitine as a candidate biomarker of sepsis outcome, and advance understanding of organ-level changes in energy homeostasis during sepsis. Collectively, these findings will contribute to fundamental knowledge of metabolic mechanisms that drive critical illness heterogeneity. These new insights will provide a precision medicine directive for the effective treatment of sepsis and ARDS, fuel the advancement of well-in- formed adaptive clinical trial design, and improve human health.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $394,805 )
2026	2026	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE STE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Biomedical Research and Research Training	000	7	1/16/2026	NON-COMPETING CONTINUATION	$394,805
														Subtotal = $394,805

Issue Date FY: 2025 ( Subtotal = $438,672 )
2025	2025	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE, SUITE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Biomedical Research and Research Training	002	6	1/24/2025	COMPETING CONTINUATION	$438,672
2025	2024	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE, SUITE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Biomedical Research and Research Training	001	5	1/16/2025	NON-COMPETING CONTINUATION	$0
2025	2024	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE STE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Biomedical Research and Research Training	003	5	6/11/2025	NON-COMPETING CONTINUATION	$0
2025	2024	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE, SUITE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Biomedical Research and Research Training	000	5	11/8/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $438,672

Issue Date FY: 2024 ( Subtotal = $382,707 )
2024	2024	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE, SUITE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Biomedical Research and Research Training	001	5	8/6/2024	NON-COMPETING CONTINUATION	$38,271
2024	2024	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE, SUITE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Biomedical Research and Research Training	000	5	12/15/2023	NON-COMPETING CONTINUATION	$344,436
														Subtotal = $382,707

Issue Date FY: 2023 ( Subtotal = $382,707 )
2023	2023	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON STREET	ANN ARBOR	MI	48109	WASHTENAW	USA	Biomedical Research and Research Training	001	4	4/5/2023	NON-COMPETING CONTINUATION	$38,271
2023	2023	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON STREET	ANN ARBOR	MI	48109	WASHTENAW	USA	Biomedical Research and Research Training	000	4	1/5/2023	NON-COMPETING CONTINUATION	$344,436
														Subtotal = $382,707

Issue Date FY: 2022 ( Subtotal = $394,719 )
2022	2022	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Biomedical Research and Research Training	002	3	6/24/2022	SUPPLEMENT FOR EXPANSION	$12,012
2022	2022	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Biomedical Research and Research Training	000	3	2/9/2022	NON-COMPETING CONTINUATION	$344,435
2022	2022	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Biomedical Research and Research Training	001	3	6/23/2022	NON-COMPETING CONTINUATION	$38,272
														Subtotal = $394,719

Issue Date FY: 2021 ( Subtotal = $382,707 )
2021	2021	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Biomedical Research and Research Training	000	2	3/5/2021	NON-COMPETING CONTINUATION	$382,707
														Subtotal = $382,707

Issue Date FY: 2020 ( Subtotal = $382,707 )
2020	2020	REGENTS OF THE UNIVERSITY OF MICHIGAN	503 THOMPSON ST	ANN ARBOR	MI	48109	WASHTENAW	USA	Biomedical Research and Research Training	000	1	2/28/2020	NEW	$382,707
														Subtotal = $382,707

Grand Total All Awards = $2,759,024

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Translational Metabolomics in Critical Care

Award Number: R35GM136312

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2020

PERIOD OF PERFORMANCE END DATE: 01/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer